Renaissance Group LLC Has $7.57 Million Stock Holdings in ADMA Biologics Inc $ADMA

Renaissance Group LLC boosted its position in ADMA Biologics Inc (NASDAQ:ADMA) by 50.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 516,588 shares of the biotechnology company’s stock after acquiring an additional 173,016 shares during the period. Renaissance Group LLC owned 0.22% of ADMA Biologics worth $7,573,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ADMA. Royal Bank of Canada boosted its stake in shares of ADMA Biologics by 112.7% in the 1st quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after purchasing an additional 50,801 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in ADMA Biologics in the first quarter valued at approximately $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock valued at $16,201,000 after buying an additional 305,064 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in ADMA Biologics by 16.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,222 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 1,312 shares during the last quarter. Finally, Ameritas Advisory Services LLC acquired a new stake in ADMA Biologics during the 2nd quarter worth $46,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Up 3.1%

Shares of NASDAQ ADMA opened at $16.43 on Friday. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The stock has a market cap of $3.91 billion, a price-to-earnings ratio of 19.10 and a beta of 0.49. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The company’s fifty day moving average is $18.35 and its 200-day moving average is $17.02.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. ADMA Biologics had a net margin of 42.87% and a return on equity of 36.52%. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.15 EPS. Equities research analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.